At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,913 enrolled
Drug / intervention
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live +4 morebiological
Likely dose
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Frozen MMRV Given Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines in Healthy Children 12 to 15 Months of Age
In Brief
A Phase 3 clinical trial evaluating Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Tripedia, and 3 other interventions for Measles and 3 related conditions. Completed, enrolled 1,913 participants.
Detailed Summary
This study will assess the safety and immunogenicity of ProQuad when administered concomitantly and nonconcomitantly with Tripedia and Comvax.
Study Details
Timeline
Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2000
Primary CompletionOct 2001
Study CompletionDec 2001
First PostedSep 2009
TodayJul 2026
First PostedSep 25, 2009
Enrollment StartJun 1, 2000
Primary CompletionOct 1, 2001
Study CompletionDec 1, 2001
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.8 years ago
Interventions
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Livebiological
A single 0.5 mL subcutaneous injection at Day 0
Comparator: Tripediabiological
A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
Comparator: Comvaxbiological
A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
Comparator: Varivaxbiological
A single 0.5 mL subcutaneous injection at Day 0
Comparator: M-M-R IIbiological
A single 0.5 mL subcutaneous injection at Day 0